瘤突变负担作为毛囊淋巴瘤的预后生物标志物

Marta Lafuente1,2, Ramón Diez-Feijóo1,2,3, Marta García-Recio4

  • 1Group of Applied Clinical Research in Hematology, Cancer Research Program Hospital del Mar Research Institute, 08003 Barcelona, Spain.

Cancers
|March 14, 2026
PubMed
概括

高瘤突变负担 (TMB) 预测毛囊淋巴瘤 (FL) 患者接受免疫化疗 (ICT) 治疗的结果更好. 这一发现有助于识别患有早期复发风险的患者,改善了超出当前临床指数的预后准确性.